Purpose: PhXA41, a new phenyl-substituted analog of a prostaglandin F2α (PGF2α) prodrug (13,14-dihydro-17-phenyl-18,19,20-trinor-prostagland in F2α-1-isopropyl ester), is an effective ocular hypotensive agent in patients with glaucoma. To understand its mechanism of action, various components of aqueous humor dynamics were examined after topical application to human eyes. Methods: In a randomized, double-masked, placebo-controlled study, PhXA41 (0.006%) was given topically twice daily for 1 week to one eye each of 22 volunteers with normotension or ocular hypertension. The other eye was similarly treated with vehicle. Intraocular pressure (IOP) was measured by pneumatonometry and tonographic outflow facility by pneumatonography. Aqueous flow and outflow facility were determined either directly or indirectly by a fluorophotometric technique, and uveoscleral outflow was calculated secondarily. Comparison of values obtained in treated versus contralateral control eyes and on baseline versus day 8 of treatment were made. Results: Compared with baseline measurements, PhXA41 significantly (P < 0.001) reduced IOP by 5.5 ± 0.6 mmHg (mean ± standard error of the mean) as measured 3 hours after the last dose on the eighth day of treatment. Aqueous flow, tonographic outflow facility, and fluorophotometric outflow facility were not changed by PhXA41. However, uveoscleral outflow was significantly greater in the PhXA41-treated eyes (0.87 + 0.22 µl/minute) compared with either the contralateral vehicle-treated eyes (0.14 ± 0.30; P < 0.02) or baseline measurements (0.39 ± 0.20 µl/minute; P < 0.05). Conclusions: PhXA41 decreases IOP in humans by increasing uveoscleral outflow without significantly affecting other parameters of aqueous humor dynamics.
ASJC Scopus subject areas